29 maj: US GAS: Futures Slump As Traders Fear Demand Declines
29 maj: US Stocks Advance; DJIA Notches Triple-Digit Gain
29-05-2012 22:39:00

UPDATE: J&J Unit Gets FDA Warning Letter On K-Y Vaginal Moisturizer

Relateret indhold

(Updates with McNeil statement starting in the third paragraph.)

--FDA warns J&J unit on failure to properly investigate some consumer complaints

--Most of the letter details problems related to K-Y vaginal moisturizer

--FDA says a reporting problem related to O.B. Tampons has been adequately addressed

By Jennifer Corbett Dooren

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration said a Johnson & Johnson (JNJ) unit didn't properly investigate consumer complaints related to a vaginal moisturizer.

The agency, in a warning letter dated May 22, said the company received more than 200 complaints about K-Y liquibeads vaginal moisturizer, which is made by McNeil PPC Inc., from June 25, 2010, through Dec. 12, 2011. The agency said the complaints included reports of the product not dissolving or having an uncharacteristic consistency or texture. FDA said some of the complaints were closed without being investigated by the company. McNeil also didn't adequately investigate some complaints that contained an incorrect lot number, according to FDA.

In a statement, McNeil said it takes the issues raised by FDA seriously. "We will respond fully to their concerns and take whatever steps are needed to resolve these issues," the company said.

The warning letter was posted to the FDA's website on Tuesday. The letter stems from an inspection conducted by the FDA of a McNeil facility in Skillman, N.J. on Dec. 12, 2011 through Jan. 19, 2012.

The FDA also said the company was late in submitting a report about a person being diagnosed with toxic shock syndrome after using an O.B. Tampon, also made by McNeil. However, the FDA said the company had adequately responded to the agency's concerns about that report.

Johnson & Johnson's McNeil Consumer Healthcare unit has been working to address manufacturing problems that led to recalls of Tylenol and other over-the-counter products starting in 2009. Three of the company's manufacturing plants were placed under an FDA consent decree last year and one of the plants, in Fort Washington, Pa., is still shut down.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

(END) Dow Jones Newswires

May 29, 2012 16:39 ET (20:39 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Danske Bank udnævner Gilbert Kohnke til kreditchef - NY

30-01-2015 15:50:19
Danske Bank har udnævnt Gilbert Kohnke til Chief Risk Officer (CRO). Han får ansvar for Group Risk Management og indtræder i bankens direktion med virkning fra ..

Mærsk: Japansk treenighed tegner et blandet rate-billede

30-01-2015 12:02:51
De tre japanske rederier MOL, NYK og K-Line har offentliggjort 3. kvartalsregnskaber for deres forskudte regnskabsår 2014/15. De tre rederier er alle repræsente..

Aktier/åbning: Aktierne er i plus i C20 - kun TDC står til fald

30-01-2015 09:30:05
Det danske aktiemarked fejrer weekendens komme med stigninger næsten over hele linjen. Kun TDC ligger i rødt i bunden af C20 Cap-indekset med et fald på 0,14 pc..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo Nordisk godt på vej med stort insulinhåb
2
Novo Q4: Opjusterede forventninger slår estimaterne i markedet
3
Aktier/tendens: Novo Nordisk kan drive aktiemarkedet op
4
OPTAKT Danske Q4 3/2: Udbyttet halter efter konkurrenter
5
Novo Q4: Klart over forventning trods lille diabetes-skuffelse

Relaterede aktiekurser

Johnson & Johnson 100,14 -2,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
31. januar 2015 04:58:42
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150130.2 - EUROWEB6 - 2015-01-31 04:58:42 - 2015-01-31 04:58:42 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x